Incyclix Bio Appoints Dr. Andrew Beelen as Vice President of Clinical Development
20 Agosto 2024 - 6:30AM
Incyclix Bio, LLC, a next-generation cell cycle control company
developing INX-315, a novel, potent and selective CDK2 inhibitor
for the treatment of advanced and resistant cancer, today announced
the appointment of Andrew Beelen, MD, as Vice President of Clinical
Development. Dr. Beelen will be responsible for progressing the
clinical development of INX-315 and brings a wealth of experience
and expertise to this pivotal leadership role.
Dr. Beelen joins Incyclix Bio with over 20 years of experience
in the pharmaceutical industry with a specialized background in
developing oncology therapeutics. Most recently, Dr. Beelen was the
Executive Director of Clinical Development at G1 Therapeutics,
Inc., where he was responsible for leading the development of
multiple clinical programs, including COSELA® (trilaciclib), a
CDK4/6 inhibitor. He has also held leadership positions at
Quintiles, Watson Laboratories, Myrexis, and GlaxoSmithKline.
Throughout his career, Dr. Beelen has led clinical development
activities across all phases of development and has provided
leadership in regulatory interactions spanning IND to NDA.
“We are delighted to welcome Andy to the Incyclix team as Vice
President of Clinical Development,” said Patrick Roberts, Pharm.D.,
Ph.D., Chief Executive Officer and Co-Founder of Incyclix Bio.
“Andy has a proven track record of successfully leading clinical
and regulatory activities for novel oncology therapeutics at all
stages of development. He joins our team at a critical period of
growth as we rapidly progress INX-315 development for cancer
patients with unmet medical needs.”
“I am thrilled to join the talented team at Incyclix Bio and
leverage my expertise to help bring INX-315 to cancer patients in
need of innovative treatment options,” said Dr. Beelen. “CDK2 is a
well-validated precision oncology target that has historically
eluded drug development efforts aimed at identifying CDK2
inhibitors with sufficient selectivity over other CDK family
members. With the development of INX-315, Incyclix has broken
through past barriers and identified a potent and selective CDK2
inhibitor with best-in-class potential.”
Dr. Beelen completed his fellowship in clinical pharmacology and
residency in internal medicine at Dartmouth Hitchcock Medical
Center. He received an MD from the State University of New York
Upstate Medical University (SUNY Upstate) and earned a Bachelor of
Science from the Albany College of Pharmacy. Dr. Beelen has
authored numerous peer-reviewed publications and abstracts and
serves on the industry advisory board of Eshelman Innovation at
UNC.
About Incyclix Bio
Incyclix Bio is a next-generation cell cycle control company
advancing precision treatments that target the aberrant
proliferation driving many cancers. The company’s lead compound,
INX-315, is a potent and selective cyclin-dependent kinase 2 (CDK2)
inhibitor in clinical development. Incyclix Bio is a scientific
leader in understanding cyclin-dependent kinases (CDKs) and their
role in the cell cycle as attractive therapeutic targets across
many tumor types, including ovarian, breast and lung cancers.
Headquartered in Research Triangle Park, NC, Incyclix Bio is
founded by pioneers in CDK inhibitor discovery, research and
development. For more information, visit incyclixbio.com.
Media Contact
Tony Plohoros908-591-2839tplohoros@6degreespr.com